{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/multiple-sclerosis/background-information/prevalence/","result":{"pageContext":{"chapter":{"id":"38108bcd-8a87-5c0b-9ae8-b9db74f1c69a","slug":"prevalence","fullItemName":"Prevalence","depth":2,"htmlHeader":"<!-- begin field f946133a-cb43-4829-8af2-a78a009c7fa9 --><h2>How common is it?</h2><!-- end field f946133a-cb43-4829-8af2-a78a009c7fa9 -->","summary":"","htmlStringContent":"<!-- begin item 3ce33e88-9fbb-4067-b37f-a78a009c7df6 --><!-- begin field a8e3c054-1639-49ea-ad7d-a78a009c7fa9 --><ul><li class=\"MsoNormal\"><strong>Multiple sclerosis (MS) is the most common non-traumatic cause of significant neurological disability in people under 40 years of age</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Harrison, 2014</a>]<strong>.</strong><ul><li class=\"MsoNormal\">In 2016, an estimated 2.3 million people worldwide and 100,000 people in the UK were living with MS [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Thompson, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Wallin, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Solari, 2020</a>].</li><li class=\"MsoNormal\">Age-standardized prevalence has increased by around 10% since 1990 [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Wallin, 2019</a>].</li></ul></li><li class=\"MsoNormal\"><strong>Onset is usually in young adulthood between the ages of 20 and 50 years</strong> — mean age at diagnosis is approximately 30 years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Montalban, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Wallin, 2019</a>].<ul><li class=\"MsoNormal\">Disease onset is rare under the age of 10 years and over the age of 60 years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Hassan-Smith, 2011a</a>].</li><li class=\"MsoNormal\">Relapsing-remitting MS is the most common pattern of disease affecting about 85% of people with MS at onset [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">NICE, 2019</a>].</li><li class=\"MsoNormal\">Primary progressive MS accounts for about 15% of people with MS overall and is disproportionately more common in people with disease onset over the age of 40 years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Hassan-Smith, 2011a</a>].</li></ul></li><li class=\"MsoNormal\"><strong>MS affects 2–3 times more women than men</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">Montalban, 2018</a>]<strong>.</strong></li><li class=\"MsoNormal\"><strong>Prevalence and incidence rates vary in different parts of the UK,</strong> in general, becoming progressively higher with more northerly populations.<ul><li class=\"MsoNormal\">The <a href=\"https://www.mstrust.org.uk/a-z/prevalence-and-incidence-multiple-sclerosis\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"56677336-ad20-4cd4-b03c-ac2500add9a2\">MS Trust</a> estimates the prevalence rates of MS to be:<ul><li class=\"MsoNormal\">290 per 100,000 in Scotland (about 15,750 people) — prevalence in the north of Scotland is particularly high.</li><li class=\"MsoNormal\">258 per 100,000 in Northern Ireland (about 4830 people).</li><li class=\"MsoNormal\">190 per 100,000 in England (around 105,450 people).</li><li class=\"MsoNormal\">179 per 100,000 in Wales (about 5600 people).</li></ul></li></ul></li><li class=\"MsoNormal\"><strong>A study by Public Health England using a sample of anonymized primary care records from 385 primary care practices in the UK (the Health Improvement Network dataset) found [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-sclerosis/references/\">PHE, 2020</a>]:</strong><ul><li class=\"MsoNormal\">That MS is more than twice as common in females than in males.</li><li class=\"MsoNormal\">Females in the 50–59 years age group are three times more likely than males of a similar age to have MS.</li><li class=\"MsoNormal\">The highest prevalence for MS occurs in the 60–69 years age group for both sexes.</li><li class=\"MsoNormal\">75% of males and females with MS are aged between 40–74 years of age.</li><li class=\"MsoNormal\">Smoking rates among males with MS are likely to be higher than those in the general population and people with MS are more likely to be ex-smokers than the general population.</li></ul></li></ul><!-- end field a8e3c054-1639-49ea-ad7d-a78a009c7fa9 --><!-- end item 3ce33e88-9fbb-4067-b37f-a78a009c7df6 -->","topic":{"id":"d4f5f727-ed37-55a1-abb1-280e5fc9851e","topicId":"5d674db8-174e-4008-be2b-97980377bc61","topicName":"Multiple sclerosis","slug":"multiple-sclerosis","lastRevised":"Last revised in August 2020","chapters":[{"id":"5bcd2220-ea7d-5aa0-b179-870dd52d1a9d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0b281488-c1a9-571c-9f76-76a0ca4f3f61","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0268dff6-e6a3-5331-9e13-7258fdfe9bdb","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ac99d001-df07-5809-9d43-3d52702e71a7","slug":"changes","fullItemName":"Changes"},{"id":"0c03fe4d-4002-5f0b-a40a-ea4925270b27","slug":"update","fullItemName":"Update"}]},{"id":"6ed54162-5487-59f3-b908-b856fb8f2150","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"952c02eb-45ac-5b32-afcc-183466bb602e","slug":"goals","fullItemName":"Goals"},{"id":"4b841ec7-26b6-5463-a184-0cdf46d3b8a5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6282c221-3df8-5a37-a525-cfaf733f007d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9c0d0509-a813-56b1-b980-801b252d4045","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"bba30032-e86d-577c-a3ca-fa9aed61784a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d4744d85-2f18-554f-b380-d3bf10688018","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"6c6f57ef-4211-5735-8895-4fda97d92881","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a50c93d9-2521-5417-ad53-bfb7f36d89f3","slug":"definition","fullItemName":"Definition"},{"id":"e8237fd3-792a-578e-b846-57b7431a7db8","slug":"causes","fullItemName":"Causes"},{"id":"0b182587-5c21-57f2-8398-ab8e98fcf8f6","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"38108bcd-8a87-5c0b-9ae8-b9db74f1c69a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"37fb0c7f-1f18-5f13-889a-245cc60a3bee","slug":"complications","fullItemName":"Complications"},{"id":"fd2cae1b-67e8-5a36-924e-cda5c20f8a6c","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"7d30fb43-cd66-5aab-af72-8e461bc91727","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ff701475-207f-5854-8697-487b8a3dc212","slug":"initial-presentation","fullItemName":"Initial presentation"},{"id":"fd10e131-3f32-5228-a05b-5a6267fef1b2","slug":"confirming-the-diagnosis","fullItemName":"Confirming the diagnosis"},{"id":"eb9fc872-e7a9-5863-bdf8-a59e3bd632f5","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"7f20e1da-bbf8-57a8-a08c-b31179f8d6f2","slug":"diagnosing-a-relapse","fullItemName":"Diagnosing a relapse"}]},{"id":"983a9545-7ebd-5a8f-bc74-2c5a7e1630f0","fullItemName":"Management","slug":"management","subChapters":[{"id":"0191f771-fc85-5664-89d2-67c7d170e292","slug":"general-management","fullItemName":"Scenario: General management"},{"id":"6c75c07e-8dff-5d76-9dd6-24617f774c7b","slug":"managing-a-relapse","fullItemName":"Scenario: Managing a relapse"},{"id":"41a80c0f-66c4-59e9-b83f-74fe33a4ea7e","slug":"managing-complications","fullItemName":"Scenario: Managing complications"}]},{"id":"edace7ac-83b8-5cf1-87da-709d39382122","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"51308a75-1f5a-5ec7-87a2-42bac2d0f697","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"492510e2-a07f-5248-9cf7-ca78c4c5dd7d","slug":"baclofen","fullItemName":"Baclofen"},{"id":"4ce98dc6-eb95-55cd-b840-e2ce178eecbe","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"10cf6767-f716-53c7-abf5-fb44584b2bea","slug":"amitriptyline","fullItemName":"Amitriptyline"}]},{"id":"e3101b52-b59a-5107-b7e1-5927f9b1ac3b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d9a4c686-396a-5209-81c6-42f9e9a35598","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8534fa8f-86c0-5a20-91f4-eb030ff54379","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"efebc734-6f42-5782-b6db-8c1dafca9d26","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3991ab27-1fd8-5fe7-b3dd-c9fb7fa1657e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e53280a5-7955-5f7d-86bb-6514173c53af","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"eb1acd9f-4671-5653-800c-75002b20feb8","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"91ad41f7-47f3-5057-a6de-8a37baf9edbc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6c6f57ef-4211-5735-8895-4fda97d92881","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}